San Francisco, CA4 Active Studies

Non-Alcoholic Fatty Liver Disease Clinical Trials in San Francisco, CA

Find 4 actively recruiting non-alcoholic fatty liver disease clinical trials in San Francisco, CA. Connect with local research sites and explore new treatment options.

4
Active Trials
2
Sponsors
378
Enrolling

Recruiting Non-Alcoholic Fatty Liver Disease Studies in San Francisco

About Non-Alcoholic Fatty Liver Disease Clinical Trials in San Francisco

Non-alcoholic fatty liver disease (NAFLD/MASLD) is a condition where excess fat builds up in the liver without significant alcohol consumption. It is the most common liver disease in Western countries. Management includes weight loss, exercise, and treatment of associated metabolic conditions.

There are currently 4 non-alcoholic fatty liver disease clinical trials recruiting participants in San Francisco, CA. These studies are seeking a combined 378 participants. Research is being sponsored by University of California, San Francisco, Naga P. Chalasani. Clinical trial participation is free and participants receive study-related medical care at no cost.

Non-Alcoholic Fatty Liver Disease Clinical Trials in San Francisco — FAQ

Are there non-alcoholic fatty liver disease clinical trials in San Francisco?

Yes, there are 4 non-alcoholic fatty liver disease clinical trials currently recruiting in San Francisco, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in San Francisco?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you about next steps.

Are clinical trials in San Francisco free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Francisco studies also compensate for your time and travel.

What non-alcoholic fatty liver disease treatments are being tested?

The 4 active trials in San Francisco are testing new therapies including novel drugs, biologics, and treatment approaches for non-alcoholic fatty liver disease.

Data updated October 15, 2026 from ClinicalTrials.gov